Abstract
Clostridioides difficile is an urgent antimicrobial-resistant bacterium, causing mild to moderate and sometimes life-threatening disease. Commensal gut microbes are critical for providing colonization resistance against C difficile and can be leveraged as non-antibiotic alternative therapeutics for the prevention and treatment of C difficile infection.
Keywords:
Clostridioides difficile; bacteria; bile acids; microbiota; short-chain fatty acids.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Publication types
-
Introductory Journal Article
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Anti-Bacterial Agents / immunology
-
Anti-Bacterial Agents / metabolism
-
Anti-Bacterial Agents / therapeutic use
-
Antibiosis
-
Bile Acids and Salts / immunology
-
Bile Acids and Salts / metabolism
-
Clostridioides difficile / drug effects
-
Clostridioides difficile / growth & development*
-
Clostridioides difficile / metabolism
-
Clostridium Infections / drug therapy
-
Clostridium Infections / immunology*
-
Clostridium Infections / microbiology
-
Fatty Acids, Volatile / immunology
-
Fatty Acids, Volatile / metabolism
-
Gastrointestinal Microbiome / drug effects
-
Gastrointestinal Microbiome / physiology
-
Humans
-
Nutrients / immunology
-
Nutrients / metabolism
Substances
-
Anti-Bacterial Agents
-
Bile Acids and Salts
-
Fatty Acids, Volatile